Assessment of cognitive performance after progesterone administration in healthy male volunteers

Neuropsychobiology

Volumn 35, Issue 3, 1997, Pages 147-151

  Grön, Georg ^a   Friess, Elisabeth ^a   Herpers, Martin ^a   Rupprecht, Rainer ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Attention; Neuroactive steroids; Neurosteroids; Progesterone

Indexed keywords

PROGESTERONE;

ADULT; ARTICLE; ATTENTION; BIOAVAILABILITY; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SLEEP; TASK PERFORMANCE;

ADULT; COGNITION; DOUBLE-BLIND METHOD; HUMANS; MALE; PROGESTERONE; TASK PERFORMANCE AND ANALYSIS;

EID: 0030960705     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119336     Document Type: Article

References (30)

1. Schmidt PJ, Purdy RH, Moore PH, Paul SM, Rubinow DR: Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994:79:1256-1260.
2. Rcdei E, Freeman EW: Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995:20: 259-267.
3. Biedermann K, Schoch P: Do neuroactive steroids cause fatigue in pregnancy? Eur J Obstet Gynecol Reprod Biol 1985;58:15-18.
4. Bitran D, Purdv RH, Kellogg CK: Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAa receptor function. Pharmacol Biochem Behav 1993:45:423-428.
5. areceptors. J Neuroendocrinol 1995;7:171-177.
6. Kavaliers M, Wiebe JP: Analgesic effects of the progesterone metabolite 3a-hydroxy-5a-preg-nan-20-one and possible modes of action in mice. Brain Res 1987;415:393-398.
7. Merryman W. Boiman R. Barnes L, Rothschild I: Progesterone ‘anaesthesia' in human subjects. J Clin Endocrinol Metab 1954; 14:1567-1569.
8. Bäckström T, Zetterlund B, Blom S, Romano M: Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol Scand 1984;69:240-248.
9. Arafat ES, Hargrove JT, Maxson WS, Desidcrio DM, Wentz AC, Andersen RN: Sedative and hypnotic effects of oral administration of nticronized progesterone may be mediated through its metabolites. Am J Obstct Gynecol 1988:159:1203-1209.
10. Freeman EW, Weinstock L, Rickels K, Sondhimer SJ, Coutfiaris C: A placebo-controlled study of effects of oral progesterone on performance and mood. Br J Clin Pharmacol 1992: 33:293-298.
11. Freeman EW, Purdy RH. Coutifaris C. Rickels K. Paul SM: Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 1993:58:478-484.
12. Herrmann WM, Beach RC: Experimental and clinical data indicating the psychotropic properties of progestogens. Postgrad Med J 1978: 54:82-87.
13. Cohen RA: The Neuropsychology of Attention. New York, Plenum Press. 1993.
14. Oswald WD, Roth E, Hogreve CJ: Der Zahlen-Verbindungs-Test (ZVT). Göttingen. Verlag tir Psychopathologie, 1987.
15. Rcitan RM: Trail Making Test: Manual for administration, scoring and interpretation, In-dianpolis, 1956.
16. Zimmermann P, Fimm B, Fimrn V: Testbalte-rie zur Aufmerksamkeitsprüfung (TAP). Version 1.02. Freiburg. 1993.
17. Maxson WS, Hargrove JT: Bioavailability of oral micronized progesterone. Fertil Steril 1991;44:622-626.
18. Norman TR, Morse CA, Dennerstein L: Comparative bioavailabilitv of orally and vaginally administered progesterone. Fertil Steril 1991; 56:1034-1039.
19. Ottoson UB, Carlstrom K, Damber JE, Von Schoulz B: Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol 1984:91:1111-1119.
20. Tapanacinen J, Kauppila A, Metsa-Ketela T, Vapaatalo H: Prostanoids and catecholamines after oral administration of natural progesterone. Gynecol Endocrinol 1989;3:135-142.
21. Broverman DM, Vogel W, Klaiber EL, Majcher D, Shea D, Paul V: Changes in cognitive task performance across the menstrual cycle. J Comp Physiol Psychol 1981;95:646-654.
22. Gordon HW. Lee PA: No difference in cognitive performance between phases of the menstrual cycle. Psychoneuroendocrinology 1993; 18:521-531.
23. Evans RM: The steroid and thyroid hormone receptor super family. Science 1988:240:889-895.
24. McEwen BS: Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 1991;12:141-147.
25. Gee KW, Bolger MB, Brinton RE, Coirini H, McEwen BS: Steroid modulation of the chloride ionophore in rat brain: Structure-activity requirements, regional dependence and mechanism of action. J Pharmacol Exp Ther 1988; 246:803-812.
26. Majewska MD, Harrison NL. Schwartz RD. Barker JL, Paul SM: Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986:232:1004-1007.
27. Paul SM, Purdy RH: Neuroactive steroids. FA-SEBJ 1992;6:2311-2322.
28. Rupprecht R, Reul JMHM, Trapp T, van Steensel B, Wetzel C, Damnt K, Zieglgansber-ger W, Holsboer F: Progesterone receptor-mediated effects of neuroactive steroids. Neuron 1993;1 1:523-530.
29. Lancel M, Faulhaber J, Holsboer F, Rupprecht R: Progesterone induces changes in sleep EEG comparable to those of agonistic GABAa receptor modulators. Am J Physiol 1996;271:E763-E772.
30. Rupprecht R, Reul JMHM, van Steensel B, Spengler D, Soder M, Beming B, Holsboer F, Dantm K: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol 1993;247:145-154.